Farydak (Panobinostat) for Myeloma

Overview

Farydak is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in people who have tried other therapies. Farydak is usually combined with Velcade and a corticosteroid. Farydak may also be referred to by its drug name, panobinostat. Farydak is an anti-cancer drug. Farydak is a member of a class of drugs called histone deacetylase inhibitors. Farydak is believed to work by killing cancer cells and slowing their growth.

How do I take it?

Farydak is taken three times per week on a specific schedule. Farydak is available as a capsule.

Side effects

The FDA-approved label for Farydak lists common side effects including diarrhea, fatigue, nausea, peripheral edema, decreased appetite, fever, and vomiting. Rare but serious side effects listed for Farydak include severe diarrhea and cardiac events, bleeding in the stomach and lungs, liver toxicity, and fetal harm.

For more details about this treatment, visit:

Farydak — Novartis https://us.farydak.com

Drug Therapy for Multiple Myeloma — American Cancer Society https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html